Ayala Pharmaceuticals, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
Ayala Pharmaceuticals has filed an amendment to its annual report on Form 10-K to include information required in Part III, which was initially omitted.
Ayala Pharmaceuticals reports a significant net loss of $48.1 million for 2023 and expresses substantial doubt about its ability to continue as a going concern after selling key assets to Immunome.